

Prediabetes Market Size, Share and Growth Outlook 2026: By Intervention, By Service and Diagnostic Type, By Age Group, Companies to 2034

<https://marketpublishers.com/r/P39BCBEC3FE4EN.html>

Date: July 2026

Pages: 190

Price: US\$ 3,482.00 (Single User License)

ID: P39BCBEC3FE4EN

Abstracts

The global Prediabetes Market size is forecast to increase from \$382.83 Million in 2026 to \$904.1 Million in 2034 at a CAGR of 11.34% between 2026 and 2034.

The Prediabetes market report provides detailed analysis and outlook of Prediabetes segments including By Intervention (Pharmacological Therapy (Drug Class), Biguanides, Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, Thiazolidinediones, SGLT2 Inhibitors, DPP-4 Inhibitors, Lifestyle and Dietary Interventions, Digital Health and Preventive Platforms), By Service and Diagnostic Type (Screening and Diagnostic Tests, Monitoring Devices), By Age Group (Children and Adolescents, Adults, Elderly / Geriatric) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Prediabetes Industry Overview

Predictive Analytics, Digital Therapeutics, and Preventive Care Models Are Reshaping Prediabetes Management

The prediabetes industry is undergoing a fundamental transformation as healthcare systems increasingly emphasize early intervention, predictive risk assessment, and digitally enabled disease prevention strategies. Growing recognition that prediabetes represents a critical window for preventing progression to type 2 diabetes has accelerated investment in continuous monitoring technologies, artificial intelligence platforms, behavioral health interventions, and digital therapeutics. Rather than relying solely on periodic laboratory measurements, emerging care models utilize real-time

physiological data, personalized lifestyle recommendations, and predictive analytics to optimize metabolic health outcomes. This transition is positioning prediabetes management as a central component of broader cardiometabolic disease prevention strategies.

Artificial Intelligence and Behavioral Analytics Are Improving Early Risk Intervention

Advanced data analytics and machine learning technologies are increasingly being deployed to identify individuals at risk of disease progression and deliver personalized interventions. Supporting this trend, DarioHealth published extensive clinical findings derived from more than 22,000 users, demonstrating how machine learning algorithms and structured behavioral reinforcement strategies can influence metabolic trajectories among individuals with prediabetes and early cardiometabolic risk factors. Similarly, digital health innovator SNAQ introduced its AI Nutritionist platform, which integrates continuous glucose monitoring data with photo-recognition algorithms to predict individualized glycemic responses to meals. These predictive capabilities enable users to make informed nutritional decisions aimed at preventing metabolic deterioration before progression to overt diabetes occurs.

Regulatory Support and Digital Health Expansion Are Accelerating Market Development

The expansion of digital health infrastructure and supportive regulatory frameworks is creating new opportunities for preventive metabolic care. Healthcare regulators increasingly recognize the role of remote monitoring, behavioral interventions, and digital therapeutics in managing chronic disease risk factors outside traditional clinical settings. Reflecting this shift, the U.S. Food and Drug Administration initiated its Technology-Enabled Meaningful Patient Outcomes (TEMPO) digital health pilot program, designed to facilitate regulatory pathways for technologies targeting low-acuity cardiometabolic conditions, including prediabetes. The initiative supports broader adoption of remote monitoring systems, digital behavior modification platforms, and preventive health technologies. Together, advances in artificial intelligence, continuous monitoring, behavioral science, and regulatory support are transforming prediabetes management from episodic screening into a proactive, precision-based preventive care ecosystem.

Prediabetes Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Prediabetes market is witnessing increasing investments in innovation,

product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca plc, Pfizer Inc., Bristol-Myers Squibb Company, Valbiotis, Aphaia Pharma AG, HighTide Biopharma Pty Ltd, Resverlogix Corp., Corcept Therapeutics. The Prediabetes market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Prediabetes industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.

The report provides detailed market analysis including-

- Growth Prediabetes Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Prediabetes companies

- Porter's Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

- Detailed SWOT Analysis of global and regional Prediabetes markets

- Competitive analysis including business description, product analysis, and financial profiles

- Key country specific analysis detailing key factors shaping the short-term and long-term outlook

- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Prediabetes Market Competitive Benchmarking and Company Analysis

Leading companies in Prediabetes industry include- Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca plc, Pfizer Inc., Bristol-Myers Squibb Company, Valbiotis,

Aphaia Pharma AG, HighTide Biopharma Pty Ltd, Resverlogix Corp., Corcept Therapeutics. The Prediabetes market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Prediabetes Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach \$8.2 Trillion in 2034 from \$5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Prediabetes market remains one of the strongest-performing segments in the country.

The US Prediabetes Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Prediabetes market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Prediabetes industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Prediabetes markets

Canada's strong Prediabetes sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Prediabetes market presents significant opportunities for U.S. exporters of medical

devices, with the U.S. being Canada's largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Prediabetes Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Prediabetes market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Prediabetes population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Prediabetes industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Prediabetes market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Prediabetes sales through 2034

France Prediabetes companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country's National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country's healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.

The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France's market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Prediabetes Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Prediabetes distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England's plan to give more than 500,000 staff access to new AI tools.

China Prediabetes Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Prediabetes market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Prediabetes industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.

The National Healthcare Security Administration reported that by end-2024, China's basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Prediabetes industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Prediabetes Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Prediabetes market is witnessing the rapid emergence of an ecosystem that

brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Prediabetes market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Prediabetes Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending.

Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Prediabetes Market Segmentation

By Intervention

Pharmacological Therapy (Drug Class)

Biguanides

Glucagon-like Peptide-1 (GLP-1) Receptor Agonists

Thiazolidinediones

SGLT2 Inhibitors

DPP-4 Inhibitors

Lifestyle and Dietary Interventions

Digital Health and Preventive Platforms

By Service and Diagnostic Type

Screening and Diagnostic Tests

Monitoring Devices

By Age Group

Children and Adolescents

Adults

Elderly / Geriatric

Leading Companies in Prediabetes Industry (2026)

Novo Nordisk A/S

Eli Lilly and Company

AstraZeneca plc

Pfizer Inc.

Bristol-Myers Squibb Company

Valbiotis

Aphaia Pharma AG

HighTide Biopharma Pty Ltd

Resverlogix Corp.

Corcept Therapeutics

Countries Included

North America- US, Canada, Mexico

Europe- Germany, France, UK, Spain, Italy, Nordics, Others

Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia,
Others

Latin America- Brazil, Argentina, Others

Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa,
Other Africa

Key Benefits of Procuring the Analysis

Get Free print authentication across single, multi, and global licenses

Free Accompanying excel spreadsheet with complete quantitative data

Free 2-day consulting support from the lead analyst of the team that developed
the report

Strategic Value of the Electrosurgical Generators Market Analysis

Gain clear understanding of current market conditions across 20 countries and
plan your decisions accordingly

Understand competitive profiles of the leading 15 companies in the
Electrosurgical Generators industry

Stay ahead of competition through a detailed analysis of recent market
developments

Make trusted decisions building on our 10-year experience in developing reports
on Electrosurgical Generators industry

Contents

CHAPTER 1- EXECUTIVE SUMMARY

- 1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
- 1.2. Key Industry Highlights, 2026
- 1.3. Premium Market Insights
 - 1.3.1. Potential Prediabetes Market Types and Applications
 - 1.3.2. Fastest Growing Countries Over the forecast period
- 1.4. Market Scope and Segmentation
 - 1.4.1. Key Market Segments
 - 1.4.2. Key Countries and Regions
 - 1.4.3. Top Companies in the Prediabetes Industry
- 1.5. Macroeconomic and Demographic Outlook
 - 1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
 - 1.5.2. Population Forecast by Country, 2010- 2040
 - 1.5.3. Inflation Trends in Leading Countries
- 1.6. Impact of Trade Policies, Regulations, and Sustainability
 - 1.6.1. Trade tariffs and localization requirements
 - 1.6.2. ESG and sustainability pressures
 - 1.6.3. Compliance-driven structural changes in the value chain

CHAPTER 2- RESEARCH METHODOLOGY

- 2.1. Report Coverage
- 2.2. Secondary Research
- 2.3. Primary Research
- 2.4. Data Triangulation
- 2.5. Market Modeling and Forecasting

CHAPTER 3- GLOBAL PREDIABETES MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034

- 3.1. An Introduction to Global Prediabetes Markets in 2026
- 3.2. Global Historic and Forecast Prediabetes Market Size Outlook, USD Million, 2021-2034
- 3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
- 3.4. Market Dynamics
 - 3.4.1. Key Prediabetes Market Driving Forces and Their Impact on Market Outlook

- 3.4.2. Short and Long-Term Trends and Insights Shaping the Future
- 3.4.3. Potential Prediabetes Market Opportunities for Industry Stakeholders
- 3.4.4. Potential Challenges across Prediabetes Value Chain

CHAPTER 4- PREDIABETES MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT

- 4.1. Porter's Five Forces Analysis
 - 4.1.1. Bargaining Power of Buyers
 - 4.1.2. Bargaining Power of Suppliers
 - 4.1.3. Threat of Substitutes
 - 4.1.4. Threat of New Entrants
 - 4.1.5. Intensity of Competitive Rivalry
 - 4.1.6. Market Attractiveness Analysis by Segment
 - 4.1.7. Market Attractiveness Analysis by Region
- 4.2. Competitive Landscape
 - 4.2.1 Market Share Analysis of Leading Prediabetes Companies
 - 4.2.2 Recent Strategic Developments
 - 4.2.3 Mergers, Acquisitions, and Partnerships
 - 4.2.4 Product Launches and Innovation Trends
 - 4.2.5 Key Success Factors
- 4.3. Value Chain Analysis
 - 4.3.1. Key Value Chain Segments
 - 4.3.2. Dominant players by value-chain stage
- 4.4. SWOT Analysis
 - 4.4.1. Key Strengths and Opportunities
 - 4.4.2. Major Weaknesses and Threats
- 4.5 Technology Roadmap
- 4.6 Regulatory and Reimbursement Landscape

CHAPTER 5- PREDIABETES MARKET OUTLOOK BY SEGMENTS

- 5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
 - 5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
 - 5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
- By Intervention
- Pharmacological Therapy (Drug Class)
- Biguanides
- Glucagon-like Peptide-1 (GLP-1) Receptor Agonists

Thiazolidinediones
SGLT2 Inhibitors
DPP-4 Inhibitors
Lifestyle and Dietary Interventions
Digital Health and Preventive Platforms
By Service and Diagnostic Type
Screening and Diagnostic Tests
Monitoring Devices
By Age Group
Children and Adolescents
Adults
Elderly / Geriatric

CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK

- 6.1. Base Case Scenario
 - 6.1.1. Definitions and Insights
 - 6.1.2. Market Size Outlook to 2034
- 6.2. Low Growth Case Scenario
 - 6.2.1. Definitions and Insights
 - 6.2.2. Market Size Outlook to 2034
- 6.3. High Growth Case Scenario
 - 6.3.1. Definitions and Insights
 - 6.3.2. Market Size Outlook to 2034

CHAPTER 7- NORTH AMERICA PREDIABETES MARKET SIZE ANALYSIS AND OUTLOOK

- 7.1. North America Prediabetes Market Overview, 2026
- 7.2. Leading Companies Operating in North America
- 7.3. Key Industry Statistics, 2026
- 7.4. North America Prediabetes Market Trends and Growth Opportunities to 2034
- 7.5. North America Prediabetes Market Size Outlook by Type
- 7.6. North America Prediabetes Market Size Outlook by Application
- 7.7. North America Prediabetes Market Size Outlook by Country
- 7.8. United States
 - 7.8.1. Key Statistics
 - 7.8.2. The US Prediabetes Market Size Outlook, 2021- 2034
 - 7.8.3. Key Market Drivers and Industry Developments in the US Prediabetes

Companies

7.9. Canada

7.9.1. Key Statistics

7.9.2. Canada Prediabetes Market Size Outlook, 2021- 2034

7.9.3. Key Market Drivers and Industry Developments in Canada Prediabetes

Companies

7.10. Mexico

7.10.1. Key Statistics

7.10.2. Mexico Prediabetes Market Size Outlook, 2021- 2034

7.10.3. Key Market Drivers and Industry Developments in Mexico Prediabetes

Companies

CHAPTER 8- EUROPE PREDIABETES MARKET SIZE ANALYSIS AND OUTLOOK

8.1. Europe Prediabetes Market Overview, 2026

8.2. Leading Companies Operating in Europe

8.3. Key Industry Statistics, 2026

8.4. Europe Prediabetes Market Trends and Growth Opportunities to 2034

8.5. Europe Prediabetes Market Size Outlook by Type

8.6. Europe Prediabetes Market Size Outlook by Application

8.7. Europe Prediabetes Market Size Outlook by Country

8.8. Germany

8.8.1. Key Statistics

8.8.2. Germany Prediabetes Market Size Outlook, 2021- 2034

8.8.3. Key Market Drivers and Industry Developments in Germany Prediabetes

Companies

8.9. France

8.9.1. Key Statistics

8.9.2. France Prediabetes Market Size Outlook, 2021- 2034

8.9.3. Key Market Drivers and Industry Developments in France Prediabetes

Companies

8.10. United Kingdom

8.10.1. Key Statistics

8.10.2. United Kingdom Prediabetes Market Size Outlook, 2021- 2034

8.10.3. Key Market Drivers and Industry Developments in the UK Prediabetes

Companies

8.11. Spain

8.11.1. Key Statistics

8.11.2. Spain Prediabetes Market Size Outlook, 2021- 2034

- 8.11.3. Key Market Drivers and Industry Developments in Spain Prediabetes Companies
- 8.12. Italy
 - 8.12.1. Key Statistics
 - 8.12.2. Italy Prediabetes Market Size Outlook, 2021- 2034
 - 8.12.3. Key Market Drivers and Industry Developments in Italy Prediabetes Companies
- 8.13. Rest of Europe
 - 8.13.1. Key Statistics
 - 8.13.2. Rest of Europe Prediabetes Market Size Outlook, 2021- 2034
 - 8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Prediabetes Companies

CHAPTER 9- ASIA PACIFIC PREDIABETES MARKET SIZE ANALYSIS AND OUTLOOK

- 9.1. Asia Pacific Prediabetes Market Overview, 2026
- 9.2. Leading Companies Operating in Asia Pacific
- 9.3. Key Industry Statistics, 2026
- 9.4. Asia Pacific Prediabetes Market Trends and Growth Opportunities to 2034
- 9.5. Asia Pacific Prediabetes Market Size Outlook by Type
- 9.6. Asia Pacific Prediabetes Market Size Outlook by Application
- 9.7. Asia Pacific Prediabetes Market Size Outlook by Country
- 9.8. China
 - 9.8.1. Key Statistics
 - 9.8.2. China Prediabetes Market Size Outlook, 2021- 2034
 - 9.8.3. Key Market Drivers and Industry Developments in China Prediabetes Companies
- 9.9. Japan
 - 9.9.1. Key Statistics
 - 9.9.2. Japan Prediabetes Market Size Outlook, 2021- 2034
 - 9.9.3. Key Market Drivers and Industry Developments in Japan Prediabetes Companies
- 9.10. India
 - 9.10.1. Key Statistics
 - 9.10.2. India Prediabetes Market Size Outlook, 2021- 2034
 - 9.10.3. Key Market Drivers and Industry Developments in India Prediabetes Companies
- 9.11. South Korea
 - 9.11.1. Key Statistics

- 9.11.2. South Korea Prediabetes Market Size Outlook, 2021- 2034
- 9.11.3. Key Market Drivers and Industry Developments in South Korea Prediabetes Companies
- 9.12. Australia
 - 9.12.1. Key Statistics
 - 9.12.2. Australia Prediabetes Market Size Outlook, 2021- 2034
 - 9.12.3. Key Market Drivers and Industry Developments in Australia Prediabetes Companies
- 9.13. Southeast Asia
 - 9.13.1. Key Statistics
 - 9.13.2. Southeast Asia Prediabetes Market Size Outlook, 2021- 2034
 - 9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Prediabetes Companies

CHAPTER 10- SOUTH AND CENTRAL AMERICA PREDIABETES MARKET SIZE ANALYSIS AND OUTLOOK

- 10.1. South and Central America Prediabetes Market Overview, 2026
- 10.2. Leading Companies Operating in South and Central America
- 10.3. Key Industry Statistics, 2026
- 10.4. South and Central America Prediabetes Market Trends and Growth Opportunities to 2034
- 10.5. South and Central America Prediabetes Market Size Outlook by Type
- 10.6. South and Central America Prediabetes Market Size Outlook by Application
- 10.7. South and Central America Prediabetes Market Size Outlook by Country
- 10.8. Brazil
 - 10.8.1. Key Statistics
 - 10.8.2. Brazil Prediabetes Market Size Outlook, 2021- 2034
 - 10.8.3. Key Market Drivers and Industry Developments in Brazil Prediabetes Companies
- 10.9. Argentina
 - 10.9.1. Key Statistics
 - 10.9.2. Argentina Prediabetes Market Size Outlook, 2021- 2034
 - 10.9.3. Key Market Drivers and Industry Developments in Argentina Prediabetes Companies
- 10.10. Rest of Latin America
 - 10.10.1. Key Statistics
 - 10.10.2. Rest of Latin America Prediabetes Market Size Outlook, 2021- 2034
 - 10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America

Prediabetes Companies

CHAPTER 11- MIDDLE EAST AND AFRICA PREDIABETES MARKET SIZE ANALYSIS AND OUTLOOK

- 11.1. Middle East and Africa Prediabetes Market Overview, 2026
- 11.2. Leading Companies Operating in Middle East and Africa
- 11.3. Key Industry Statistics, 2026
- 11.4. Middle East and Africa Prediabetes Market Trends and Growth Opportunities to 2034
- 11.5. Middle East and Africa Prediabetes Market Size Outlook by Type
- 11.6. Middle East and Africa Prediabetes Market Size Outlook by Application
- 11.7. Middle East and Africa Prediabetes Market Size Outlook by Country
- 11.8. Saudi Arabia
 - 11.8.1. Key Statistics
 - 11.8.2. Saudi Arabia Prediabetes Market Size Outlook, 2021- 2034
 - 11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Prediabetes Companies
- 11.9. United Arab Emirates
 - 11.9.1. Key Statistics
 - 11.9.2. The UAE Prediabetes Market Size Outlook, 2021- 2034
 - 11.9.3. Key Market Drivers and Industry Developments in the UAE Prediabetes Companies
- 11.10. Africa
 - 11.10.1. Key Statistics
 - 11.10.2. Africa Prediabetes Market Size Outlook, 2021- 2034
 - 11.10.3. Key Market Drivers and Industry Developments in Africa Prediabetes Companies

CHAPTER 12- COMPANY PROFILES

- 12.1. Top Companies in Prediabetes Industry
 - Novo Nordisk A/S
 - Eli Lilly and Company
 - AstraZeneca plc
 - Pfizer Inc.
 - Bristol-Myers Squibb Company
 - Valbiotis
 - Aphaia Pharma AG

HighTide Biopharma Pty Ltd

Resverlogix Corp.

Corcept Therapeutics

12.2. Business Description

12.3. SWOT Profiles

12.4. Products and Services

CHAPTER 13- APPENDIX

Glossary of Terms

Research Methodology & Data Sources

Conclusion & Strategic Recommendations

I would like to order

Product name: Prediabetes Market Size, Share and Growth Outlook 2026: By Intervention, By Service and Diagnostic Type, By Age Group, Companies to 2034

Product link: <https://marketpublishers.com/r/P39BCBEC3FE4EN.html>

Price: US\$ 3,482.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P39BCBEC3FE4EN.html>